title: Cyclic stretch regulates autocrine IGF-I in vascular smooth muscle cells: implications in vascular hyperplasia.
abstract: Vascular smooth muscle cells (VSMC) subjected to acute or chronic stretch display enhanced growth rates in vitro and in vivo. Clinical examples of vascular hyperplasia (e.g., systolic hypertension and postinjury restenosis) suggest that local insulin-like growth factor I (IGF-I) expression is enhanced. Therefore, we investigated the role of in vitro cyclic stretch on rat VSMC IGF-I secretion and cellular growth. In serum-free medium, cyclic stretch (1 Hz at 120% resting length for 48 h) stimulated thymidine incorporation approximately 40% above that seen in nonstretched cells. Graded stretch magnitude (100-125% resting length) yielded graded increases in VSMC growth. Exogenous IGF-I increased growth of serum-starved, nonstretched VSMC in a dose-dependent manner, with maximal growth seen with 10(-7) M. IGF-I secretion from stretched cells was 20- to 30-fold greater than from those cells cultured in a static environment. Stretch-induced increases in growth were completely blocked on addition of anti-IGF-I and partially blocked with platelet-derived growth factor (PDGF) antibodies and with a tyrosine kinase inhibitor (tyrphostin-1). Finally, blockade of stretch-activated cation channels with GdCl3 profoundly inhibited stretch-induced growth. We conclude that stretch increases VSMC IGF-I secretion and that such autocrine IGF-I is required for stretch-induced growth. PDGF and stretch-sensitive cation channels are likely additional components of a complex pathway that regulates stretch-induced VSMC seen in systolic hypertension and postinjury restenosis.
authors: Department of Physiology, Midwestern University, Glendale, Arizona 85308, USA. pstand@arizona.midwestern.edu
authors: P R
authors: PR
authors: Standley
authors: T J
authors: TJ
authors: Obards
authors: C L
authors: CL
authors: Martina
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D001011:Aorta; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival; D002478:Cells, Cultured; D017077:Culture Media, Conditioned; D004261:DNA Replication / Q000187:drug effects; D005682:Gadolinium / Q000494:pharmacology; D006965:Hyperplasia; D007334:Insulin-Like Growth Factor I / Q000235:genetics* / Q000378:metabolism / Q000494:pharmacology; D008955:Models, Cardiovascular; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000473:pathology / Q000502:physiology*; D010982:Platelet-Derived Growth Factor / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains; D013314:Stress, Mechanical; D013997:Time Factors
chemical_list: D000906:Antibodies; D002121:Calcium Channel Blockers; D017077:Culture Media, Conditioned; D010982:Platelet-Derived Growth Factor; D007334:Insulin-Like Growth Factor I; D005682:Gadolinium; C038958:gadolinium chloride